Skip to content
Head to head

Spyre Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: SYRE · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

SYRE +283.7%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
SYREVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price93.47515.02
Change today-4.26%-1.08%
1-year return+298.3%+22.0%
Market cap$8.88B$130.58B
52-week range24.58 – 110.64412.27 – 568.67
Valuation
P/E (TTM)-33.6233.14
P/E percentile, own 5-yr range8th99th
P/B9.816.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-1.9815.32
Net profit (TTM)$-188.04M$3.88B
Revenue (TTM)$0$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin-22897.1%33.1%
Net margin-52939.7%30.7%
Free cash flow (TTM)$-249.32M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership106.9%96.8%
Insider activity (12mo)13 buy / 37 sell28 buy / 22 sell
Short interest (% of float)12.6%1.9%
Analyst consensus100% buy (13)95% buy / 5% hold (21)
Analyst price target$123 (+32%)$624 (+21%)
StockVane view
StockVane Quant RatingC (100)C (68)
Company
Employees1026,400
Founded20131989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.